You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Epic may also develop a liquid biopsy test combining the chromosomal instability biomarker with other markers to predict prostate cancer treatment response.
More groups are now using CTC capture methods alongside circulating tumor DNA tools to distinguish themselves from the crowded ctDNA detection space.
Research groups and companies are developing and applying tools to enrich for and capture CTCs to diagnose tumors early and monitor patients during treatment.
Epic Sciences will donate its No Cell Left Behind platform to the clinical trial, which will enroll about 1,000 patients over three years.
The decision, issued by Medicare Administrative Contractor Palmetto GBA, is effective Dec. 10 and provides coverage of the test for about 25,000 Medicare patients.
New data has shown that the firm's platform could help stratify patients for treatment with antibody-drug conjugates by finding those whose CTCs express enough of the target.
The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.
Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.
A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.